

Tele No.011-23236965  
Fax.No.011-23236973

**F. No. ND/CT/24/000029**  
**Government of India**  
**Directorate General of Health Services**  
**Central Drugs Standard Control Organization**  
**(New Drugs Division)**

FDA Bhawan, Kotla Road,  
New Delhi-11 0002  
Dated: 08.10.2024

To  
M/s Hetero Labs Limited,  
Hetero Corporate, 7-2-A2 Industrial Estate,  
Sanath Nagar Hyderabad (India) – 500055

**Subject: Application for permission to conduct Phase-III CT of Tedizolid Phosphate tablets 200mg and Tedizolid Phosphate for injection 200mg/vial titled "A Prospective, Multi-centric, Double blind, Double dummy, Randomized, Active-Controlled, Parallel Study to Compare the Efficacy, Safety and Tolerability of Tedizolid Phosphate 200mg and Linezolid 600mg for the treatment of adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) [Protocol no.: HCR/III/TEDABS/03/2024, Version No. 1.0 dated: 26-03-2024-regarding.**

Sir,

With reference to your application no. **ND/CT04/FF/2024/42678** dated **17.04.2024**; please find enclosed herewith the permission in **Form CT-06, vide No. ND/CT/24/000029** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

**Yours faithfully**  
RAJEEV SINGH  
RAGHUVANSHI  
**(Dr. Rajeev Singh Raghuvanshi)**  
**Drugs Controller General (India)**

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, 2.5.4.20=42d7189b1c0981b5a263a4a73d02584b11b680a91808773480400a43ee361b, postalCode=110002, st=Delhi, serialNumber=65715e4749409854803bd902d0e1fc73cf a12a1a126ee94fa5701124a19013, cn=RAJEEV SINGH RAGHUVANSHI  
Date: 2024.10.08 12:07:39 +05'30'

## Conditions of permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:  
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:  
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the

trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;

- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in *accordance* with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

**FORM CT-06***(See rules 22, 25, 26, 29 and 30)***PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG**

The Central Licensing Authority hereby permits **M/s Hetero Labs Limited, Hetero Corporate, 7-2-A2 Industrial Estate, Sanath Nagar, Hyderabad (India) - 500055**  
**Telephone No.: 040-23704923 FAX: 040- E-Mail :LAKSHMI.G@HETERODRUGS.COM** to conduct clinical trial of the new drug as per Protocol Number: **HCR/III/TEDABS/03/2024, Version no. 1.0, dated: 26-03-2024** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:

<b>Names of the new drug or investigational new drug:</b>	<b>Tedizolid Phosphate tablets 200mg and Tedizolid Phosphate for injection 200mg/vial</b>
<b>Therapeutic class:</b>	<b>Antibacterial</b>
<b>Dosage form:</b>	Tablets/Injection
<b>Composition:</b>	Each film coated Tablet Contains: Tedizolid Phosphate...200 milligram (mg)  Each vial Contains: Tedizolid Phosphate for injection...200 milligram (mg)
<b>Indications:</b>	<ul style="list-style-type: none"> <li>Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and adolescents 12 years of age and older.</li> </ul>
<b>Details of clinical trial sites-</b>	
<b>Sr. No.</b>	<b>Name of Principal Investigator &amp; Trial Sites</b>
<b>Ethics Committee Name/ Registration Number</b>	
1.	<b>Dr. K M V S Suman,</b> ACSR Government Medical College and Hospital, ACSR Government Medical College and Hospital ,Department of General Surgery, Daragamitta,Nellore Andhra Pradesh -524004
	Institutional Ethics Committee, ACSR Government Medical College &Hospital, Dargamitta, Nellore 524004, Andhra Pradesh  <b>ECR/961/Inst/AP/2017/RR-20</b>
2	<b>Dr Sudhir Kumar, MLB</b> Medical College, Department of Plastic Surgery, Kanpur
	Ethics committee, M.L.B Medical college Ethics Committee, MLB Medical college MLB Medical

	Road, Jhansi-284128, Uttarpradesh, India	College and Associated Hospitals, Kanpur Road, Jhansi, 284128, Uttar Pradesh  <b>ECR/1393/Inst/UP/2020</b>
3	<b>Dr Gunvant Rathod</b> , Dr. M.K. Shah Medical College and Research Centre and Smt S.M.S. Multispeciality Hospital., Dr.M.K. Shah Medical College and Research Centre and Smt SMS Multispeciality Hospital, Near Tapovan Circle, Visat- Gandhinagar, Highway, Chandkheda Ahmedabad, Gujarat - 382424	Institutional Ethics Committee Dr. M.K. Shah Medical College & Research Centre Opp. Akshar Complex, Near Tapovan Circle, Visat- Gandhinagar, Highway, Chandkheda Ahmedabad Gujarat -382424 India  <b>ECR/1383/Inst/GJ/2020</b>
4	<b>Dr Binay Krishna Sarkar</b> , Ratan Sircar Medical College and Hospital, Nil Ratan Sircar Medical College and Hospital 138, AJC Bose Road, Kolkata West Bengal, India-700014	Institutional Ethics Committee Nil Ratan Sircar Medical College and Hospital, 138 AJC Bose road, Kolkata -700014, West Bengal, India  <b>ECR/609/Inst/WB/2014/RR-20</b>
5	<b>Dr Shiv Kumar Bunkar</b> , Jawahar Lal Nehru Medical College, Jawahar Lal Nehru Medical College, Kala Bagh, Ajmer-Rajasthan - 305001	Institutional Ethics Committee Jawahar Lal Nehru Medical College, Kala Bagh, Ajmer-305001, Rajasthan  <b>ECR/1156/Inst/RJ/2018/RR-22</b>
6	<b>Dr Prashant Gupta</b> , S N Medical College, S.N Medical College Near Central Library Moti Katra, Mantola, Agra- Uttar Pradesh - 282003	Institutional Ethics Committee S.N Medical College Near Central Library Moti Katra, Mantola, Agra-282003 Uttar Pradesh  <b>ECR/1409/Inst/UP/2020</b>
7	<b>Dr Suraj Kumar Pattnayak</b> , Government Medical College and Govt General Hospital, Government Medical College and Govt General Hospital Old RIMSGGH Srikakulam Andhra	Institutional Ethics Committee Government Medical College & Govt General Hospital (Old RIMSGGH) Srikakulam 532001, Andhra Pradesh, India  <b>ECR/492/Inst/AP/2013/RR-20</b>

Pradesh,india srikakulam Andhra Pradesh - 532001	
---	--

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

**RAJEEV SINGH  
RAGHUVANSHI**  
**(Dr. Rajeev Singh Raghuvanshi)**  
**Central Licensing Authority**  
**Stamp**

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL  
ORGANISATION, ou=CENTRAL DRUGS STANDARD  
CONTROL ORGANISATION,  
2.5.4.20=42d7189b1c0981bb5a263a4e73d025f4b11b680a  
91f0873480400a43ee361b, postalCode=110002, st=Delhi,  
serialNumber=657fbc942d940985d8f03bdc902d0e11e73cfa  
12a1a125c08f462701124a19013, cn=RAJEEV SINGH  
RAGHUVANSHI  
Date: 2024.10.08 12:57:57 +05'30'

**New Delhi**  
Dated: 08.10.2024